Our Pricing

What Are The Doses Of Wegovy - Complete Range Available

Understanding the wegovy doses uk available is essential before starting your weight loss journey. Wegovy (semaglutide) is supplied in five graduated strengths—0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg—designed to minimise side effects whilst maximising efficacy through a carefully structured titration schedule [1]. At Cured Pharmacy, all Wegovy doses are available from £79.00, with transparent pricing shown before your free clinical consultation.

The Five Wegovy Doses Explained

Wegovy is available in five distinct pen strengths, each delivering a precise weekly dose of semaglutide. The 0.25mg starter dose introduces the medication gradually, allowing your body to adapt to the GLP-1 receptor agonist mechanism [1]. This initial strength is typically used for the first four weeks of treatment.

The subsequent doses—0.5mg, 1mg, and 1.7mg—represent incremental steps in the titration schedule, each maintained for four weeks subject to tolerability. The maintenance dose of 2.4mg is where most patients achieve optimal weight loss results, with clinical trials demonstrating an average 14.9% body weight reduction over 68 weeks at this strength [2].

Each pre-filled pen contains four weekly doses, making the treatment convenient and reducing the risk of dosing errors. Your UK prescriber will determine your starting dose and progression schedule based on your medical history and response to treatment.

Wegovy Dosing Schedule: How Titration Works

The Wegovy titration protocol follows a structured 16-week escalation period before reaching the maintenance dose. This gradual approach significantly reduces the incidence of gastrointestinal side effects, which are the most commonly reported adverse events with GLP-1 receptor agonists [1][3].

Weeks 1-4 begin with the 0.25mg dose, followed by 0.5mg during weeks 5-8. The dose increases to 1mg for weeks 9-12, then 1.7mg for weeks 13-16. From week 17 onwards, patients typically remain on the 2.4mg maintenance dose, though your prescriber may adjust this based on your individual response and tolerability.

If you experience persistent side effects at any stage, your UK prescriber may recommend staying at your current dose for an additional four weeks before escalating. This flexibility ensures treatment remains tolerable whilst still progressing towards the therapeutic dose.

What If I Miss a Dose?

If you miss a Wegovy injection and it has been less than two days since your scheduled dose, administer it as soon as you remember. If more than two days have passed, skip the missed dose entirely and resume your normal schedule with the next weekly injection [1].

Never double up on doses to compensate for a missed injection. If you have missed more than two consecutive doses, contact your prescriber before resuming treatment, as you may need to restart at a lower dose to maintain tolerability.

Clinical Evidence Behind Wegovy Doses UK

The STEP clinical trial programme established the efficacy and safety profile of semaglutide 2.4mg for weight management. In the pivotal STEP 1 trial, participants receiving the full 2.4mg maintenance dose achieved a mean weight loss of 14.9% compared to 2.4% with placebo over 68 weeks [2].

Importantly, the graduated dosing schedule used in these trials matches the titration protocol prescribed in UK clinical practice. This evidence-based approach demonstrated that 86.4% of participants in STEP 1 achieved at least 5% weight loss, whilst 50.5% achieved 15% or greater reduction [2].

The lower starter doses (0.25mg and 0.5mg) are not intended as therapeutic doses for weight loss but serve a critical role in building tolerability. Data from the STEP trials showed that gradual dose escalation reduced treatment discontinuation rates due to gastrointestinal adverse events by approximately 30% compared to more rapid titration schedules [3].

Long-Term Maintenance at 2.4mg

Once you reach the 2.4mg maintenance dose, this strength is typically continued long-term for sustained weight management. The STEP 4 trial demonstrated that patients who discontinued Wegovy after 20 weeks regained approximately two-thirds of their lost weight, highlighting the importance of ongoing treatment [4].

Your UK prescriber will review your progress regularly, typically every three months, to assess continued efficacy and tolerability. Some patients may remain on 1.7mg as their maintenance dose if they achieve their weight loss goals or experience side effects at the higher strength.

Comparing Wegovy Doses to Other Weight Loss Treatments

Understanding how Wegovy's dosing structure compares to alternative treatments helps inform your choice of medication. Saxenda (liraglutide) requires daily injections titrated up to 3mg, whilst Wegovy's once-weekly administration offers greater convenience for many patients.

Mounjaro (tirzepatide) follows a similar weekly injection schedule but uses a different dosing range, starting at 2.5mg and escalating to a maximum of 15mg. The dual GIP/GLP-1 mechanism of tirzepatide produces different efficacy outcomes compared to Wegovy's selective GLP-1 action [5].

Oral options like Mysimba (naltrexone/bupropion) and Orlistat work through entirely different mechanisms and do not require dose titration in the same structured manner. Your UK prescriber will recommend the most appropriate treatment based on your medical history, BMI, comorbidities, and personal preferences.

Side Effects Across Different Wegovy Doses

Gastrointestinal side effects—including nausea, diarrhoea, vomiting, and constipation—are dose-dependent with Wegovy. In the STEP trials, these symptoms were most common during dose escalation phases and typically diminished over time as patients adapted to each strength [3].

At the 0.25mg and 0.5mg starter doses, approximately 20-25% of patients reported mild nausea, which generally resolved within 2-3 weeks. At the 2.4mg maintenance dose, nausea incidence increased to around 44%, though most cases were transient and classified as mild to moderate in severity [2][3].

Serious side effects are rare but can occur at any dose. These include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other glucose-lowering medications). Your prescriber will monitor for these complications throughout your treatment journey.

If side effects become intolerable at any dose, do not discontinue Wegovy without consulting your UK prescriber. They may recommend temporarily staying at your current dose, implementing dietary modifications, or adjusting the timing of your injection to improve tolerability.

Managing Nausea During Dose Escalation

Eating smaller, more frequent meals rather than large portions can significantly reduce nausea when starting or increasing your Wegovy dose. Avoiding high-fat, greasy foods and staying well-hydrated also helps minimise gastrointestinal discomfort.

Some patients find that administering their injection in the evening rather than morning reduces daytime nausea. Discuss timing strategies with your prescriber to optimise tolerability whilst maintaining consistent weekly dosing.

Getting Wegovy Doses UK at Cured Pharmacy

At Cured Pharmacy, all five Wegovy doses are available from £79.00, with pricing displayed transparently before you begin your free online consultation. Our UK-registered clinical team, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), assesses every request to ensure Wegovy is clinically appropriate for your circumstances.

The consultation process takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. If approved, your prescription is issued by a UK prescriber and dispensed from our GPhC-registered pharmacy (9012511) with discreet next-day delivery available.

We supply only genuine UK-licensed Wegovy pens manufactured by Novo Nordisk, ensuring you receive authentic medication with full product traceability. Each pen is accompanied by comprehensive patient information leaflets detailing proper injection technique, storage requirements, and what to do if you experience side effects.

Your treatment journey includes ongoing support from our clinical team. If you have questions about dose escalation, managing side effects, or adjusting your injection schedule, our pharmacists are available via phone ((+44) 116 4646009) or through your online account dashboard.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
4. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity.